Yescarta (axicabtagene ciloleucel) / Cabaret Biotech, National Cancer Institute, Gilead, Fosun Kite - LARVOL DELTA

A phase 2 study of prophylactic intrathecal chemotherapy to prevent high-grade immune effector cell–associated neurotoxicity syndrome (ASH 2025) - "While prophylactic corticosteroids and cytokine-directed therapies like the IL-1 receptor antagonist anakinra have been explored, they carry potential risks and inconsistent efficacy...Study Design and This is a single-center, open-label, phase 2 trial evaluating the prophylactic use of IT methotrexate (12 mg), cytarabine (50 mg), and hydrocortisone (50 mg) in patients receiving standard-of-care axi-cel or brexu-cel for relapsed/refractory large cell or mantle cell lymphoma respectively...If effective, this approach could reduce the need for systemic corticosteroids, which are associated with significant morbidity. Further, prophylactic intrathecal therapy may be generalizable across existing and emerging CAR T-cell platforms, expanding eligibility to patients who might otherwise be excluded due to a high risk of neurologic toxicity."

P2 data • Acute Lymphocytic Leukemia • Brain Cancer • CNS Disorders • Epilepsy • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma

Real-world incidence of HLH-like syndromes across CAR T-cell products: A multi-institutional cohort study using the trinetx network (ASH 2025) - "Adult patients (aged ≥18 years) who received one of four U.S. Food and Drug Administration-approved CAR T-cell therapies—axicabtagene ciloleucel (Axi-cel), tisagenlecleucel (Tisa-cel), lisocabtagene maraleucel (Liso-cel), or idecabtagene vicleucel (Ide-cel) between 2017 and 2024 were included. In this large, multi-institutional real-world study, HLH-like syndromes were observed following all CAR T-cell products, with notable variation in incidence by agent. Idecabtagene vicleucel and tisagenlecleucel were associated with the highest 30-day HLH incidence, while axicabtagene ciloleucel had the lowest. These findings highlight the need for product-specific clinical vigilance and may inform post-infusion monitoring protocols."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Hemophagocytic lymphohistiocytosis • Immunology • Inflammation • Rare Diseases

primary breast lymphoma: A 10-year retrospective case series on clinical features, diagnostic imaging, and outcomes from a diverse population treated at mount sinai medical center in miami beach (ASH 2025) - "PBL management included radiotherapy in 5 pts (2 pts with concomitant Rituximab and 1 with R-CHOP), and chemoimmunotherapy alone in 3 pts (1 Hyper-CVAD and 2 R-CHOP)...Two pts failed initial therapy: one experienced progression with secondary central nervous system involvement, and the other had refractory Richter's transformation from CLL (s/p multiple treatments including axicabtagene ciloleucel)...Our findings contribute to the limited literature on breast lymphoma and underscore the importance of tailored monitoring of Hispanic pts as well as breast cancer survivors. Larger multi-center studies are needed to confirm our findings."

Retrospective data • B Cell Lymphoma • Breast Cancer • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • HER2 Breast Cancer • HER2 Positive Breast Cancer • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Richter's Syndrome • Solid Tumor • Waldenstrom Macroglobulinemia • HER-2 • PGR

Efficacy and safety of CAR-t cell therapy in richter transformation: A systematic review (ASH 2025) - "Lymphodepletion regimens included fludarabine/cyclophosphamide (FC) or bendamustine. CAR-T products administered were axi-cel (n=148), tisa-cel (n=131), liso-cel (n=57), brexu-cel (n=1), and investigational agents (n=29)... CAR-T therapy shows promising initial responses in RT, with ORR and CR rates comparable to de novo DLBCL. However, responses are often short-lived, with inferior PFS and OS compared to outcomes in aggressive lymphoma trials. RT patients face higher toxicity—particularly ICANS, cytopenias, and infections—reflecting disease biology and prior treatments."

CAR T-Cell Therapy • Clinical • IO biomarker • Review • B Cell Lymphoma • Chronic Lymphocytic Leukemia • CNS Disorders • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Richter's Syndrome • Thrombocytopenia • IGH • TP53

Real-world outcomes of autologous CD19-directed CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A single-center experience (ASH 2025) - "Twenty-two patients (73.3%) received R-CHOP as first-line chemoimmunotherapy...Two patients (6.7%) had prior anti-CD19 therapy, five (16.7%) had bendamustine exposure, and all patients received prior anti-CD20 monoclonal antibody...The most commonly used CART product was axicabtagene ciloleucel (N=28, 93%)...Tocilizumab was administered in 19 patients (63.3%), with 13 (68.4%) requiring only one dose...All ICANS patients received steroids, and four (33.3%) received anakinra...These findings affirm the safety and efficacy of autologous CD19-directed CAR T-cell therapy in routine clinical practice at a medium-sized academic institution. Continued research with larger sample sizes and extended follow-up periods is warranted to validate these results further."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia

Comparative safety profiles of bispecific T-cell engagers and CAR-T therapies: Real-world insights from the FDA adverse event reporting system database (ASH 2025) - "BiTEs demonstrated a significantly higher disproportionality signal for neutropenia compared to CAR-T therapies (PRR=1.74, ROR=1.93, 95% CI [1.89, 1.98], p<0.001), with Glofitamab showing the highest reporting rate (42.2%) among BiTEs...Tisagenlecleucel had the highest hepatotoxicity rate (4.1%) among CAR-T agents...Axicabtagene ciloleucel had the highest venous thrombosis rate (42.6%) among CAR-T agents...Brexucabtagene autoleucel had the highest rate of arterial thrombosis (0.78%) among CAR-T agents. This real-world analysis reinforces the well-characterized neurotoxicity associated with CAR-T therapies, while highlighting the higher rate of neutropenia with BiTEs. These distinct toxicity profiles emphasize the importance of individualized treatment selection, considering patient comorbidities, toxicity tolerance, logistical factors, and the clinical context, which includes the potential for better disease control with specific therapies."

Adverse events • Clinical • Real-world • Real-world evidence • Acute Kidney Injury • Cardiovascular • Hematological Malignancies • Hepatology • Nephrology • Neutropenia • Renal Disease • Thrombosis • ROR1

Real-world analysis of axicabtagene ciloleucel (axi-cel) as consolidation therapy following first-line treatment in B-cell lymphoma with high-risk factors (ASH 2025) - "All 4 DLBCL patients received R-CHOP or R-CHOP-like regimens as 1L therapy, while the MCL patient received bendamustine and rituximab (BR) as 1L therapy. Consolidation therapy with CAR-T following 1L treatment demonstrated encouraging rates of CMR, PFS, and OS in B-cell lymphoma patients with high risk of relapse. Administration of PD-1 inhibitors and/or IL-2 post-infusion may support sustained expansion and persistence of CAR-T cells. The safety profile was manageable: all CRS were mild, and no ICANS were observed, providing a valuable insight for CAR-T consolidation following 1L treatment."

Clinical • IO biomarker • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Hepatology • Large B Cell Lymphoma • Leukopenia • Liver Failure • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Thrombocytopenia • IL2

Incidence of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections and cardiovascular events across different chimeric antigen receptor (CAR) T-cell therapy products in large B-cell lymphoma (DLBCL): A nationwide analysis (ASH 2025) - "Three CAR T-cell products have received approval: axicabtagene ciloleucel (Yescarta), lisocabtagene maraleucel (Breyanzi), and tisagenlecleucel (Kymriah). The limitations of our study include its retrospective nature, reliance on ICD-10 codes to identify patients with adverse events, and the absence of longitudinal data on long-term adverse events. Nevertheless, this study provides essential insights for hematologists regarding the incidence of specific adverse events associated with different CAR T-cell products within the real-world population."

Cytokine release syndrome • B Cell Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Myocardial Infarction • Non-Hodgkin’s Lymphoma • Pneumonia • Respiratory Diseases • Septic Shock

Analysis of the cost-effectiveness without compromising clinical outcomes in outpatient CD19-directed CAR-T therapy in non-Hodgkin lymphoma patients at a community-based medical center (ASH 2025) - "Secondary objectives included assessment of toxicity, response, and survival in patients receiving axicabtagene ciloleucel (axi-cel), brexucabtagene autoleucel (brexu-cel), lisocabtagene maraleucel (liso-cel), or tisagenlecleucel (tisa-cel)...In 2024, one patient received prophylactic dexamethasone prior to infusion... Based on CMS data and the ZUMA-1 trial, the median inpatient stay for CAR-T therapy is approximately 15 days, with Medicare reimbursing an average of $498,700 per admission. This includes the high cost of the CAR-T product and the intensive inpatient care needed to manage toxicities like CRS and ICANS. In contrast, a typical 7-day inpatient hospital stay costs Medicare only $13,000 to $18,000."

Clinical • Clinical data • Cost effectiveness • HEOR • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Nodal Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma

Outcomes with itacitinib prophylaxis for cytokine release syndrome: A systematic review (ASH 2025) - "Patients were planned to receive axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma (rrLBCL). Itacitinib prophylaxis may prevent high-grade CRS and other immune-mediated adverse events such as ICANS and GVHD without reducing the treatment responses. Future high-quality trials with larger patient populations are required to validate these findings further."

Cytokine release syndrome • Review • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • B Cell Lymphoma • Graft versus Host Disease • Hematological Malignancies • Immunology • Inflammation • Large B Cell Lymphoma • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma

Aberrant lymphocytes are associated with increased inflammatory complications following CAR-T infusion (ASH 2025) - "CAR-T products included axi-cel (Yescarta) (n=10), brexu-cel (Tecartus) (n=2), liso-cel (Breyanzi) (n=1), tisa-cel (Kymriah) (n=1), or CD19-Car_Lenti (produced by the Officina Farmaceutica of Bambino Gesù Children's Hospital) (n=2)...Associations were not found between number of aberrant lymphocytes and development of neurotoxicity (eg, ICANS) nor with doses of Tocilizumab, Dexamethasone, or Anakinra or with WBC. While the number of patients is small, presence of increased aberrant lymphocytes, as pre-classified by the Scopio full-field digital morphology platform, appears to be associated with increased inflammatory complications following CAR-T infusion, including CRS of grade ≥2 and prolonged neutropenia requiring G-CSF support. Digital morphology combined with artificial intelligence may represent a novel platform for predicting clinical outcomes in CAR-T therapy."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Rheumatology

Comparative efficacy and safety of bendamustine versus fludarabine and cyclophosphamide as lymphodepleting regimens for CAR-T therapy in hematological malignancies: A systematic review and meta-analysis (ASH 2025) - "Axicabtagene ciloleucel was used in four studies, brexucabtagene autoleucel and tisagenlecleucel in two studies, and lisocabtagene maraleucel, idecabtagene vicleucel, and ciltacabtagene autoleucel in one study each. These findings suggest that bendamustine may serve as a viable alternative LD regimen, especially for patients at high risk of infections. Further prospective studies are warranted to confirm the safety and efficacy of bendamustine compared to standard FluCy regimen."

Retrospective data • Review • Acute Lymphocytic Leukemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

CAR t-cell therapy-related cytokine release syndrome and neurotoxicity: Real-world outcomes from a comprehensive cancer center (ASH 2025) - "Treatment options included ciltacabtagene autoleucel, brexucabtagene autoleucel, and axicabtagene ciloleucel...Secondary outcomes included use of tocilizumab, corticosteroids, vasopressors, anakinra, intrathecal chemotherapy, dasatinib, and thiamine; length of stay; survival at 100 days and 1 year... 53 patients were included in the study. Most patients receiving axi-cel experienced grade 1 or 2 CRS, with only three patients experiencing grade ≥3 CRS. The incidence of CRS was lower here compared to ZUMA-1 and ZUMA-5."

CAR T-Cell Therapy • Clinical • Cytokine release syndrome • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Incidence and outcomes of Clostridioides difficile infection in BCMA and CD19 CAR-T cell therapy. (ASH 2025) - "Among individual CAR-T products, the incidence was: for CD19-directed CAR-T, Brexu-cel 5%, Axi-cel 6%, Tisa-cel 5%, and Liso-cel 3%; for BCMA-directed CAR-T, Ide-cel 4% and Cilta-cel 5%. In patients with hematologic malignancies, identifying risk factors and rates of CDI in CAR-T cell therapy is essential for prompt recognition and effective management. Future research on optimizing CDI screening protocol and prevention strategies can help reduce mortality and morbidity in this immunocompromised population."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma

Title: Association of CAR-T product type with incidence of cancer Therapy–Related cardiac dysfunction (CTRCD) (ASH 2025) - " Five CAR-T products were evaluated for their association with CTRCD: axicabtagene ciloleucel, idecabtagene vicleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, and ciltacabtagene autoleucel. In this retrospective study of CAR-T recipients, the overall incidence of cancer therapy-related cardiac dysfunction (CTRCD) was notable at 39%, with variability observed across CAR-T products. Axicabtagene ciloleucel demonstrated the highest rate of CTRCD, while no events were seen with brexucabtagene autoleucel or ciltacabtagene autoleucel. Despite these trends, statistical analyses did not reveal a significant association between CAR-T product type and CTRCD incidence."

Hematological Malignancies • Immunology • Oncology • Systemic Inflammatory Response Syndrome • IL6

Impact of pulmonary and cardiac comorbidities on cytokine release syndrome incidence in chimeric antigen receptor (CAR) t-treated diffuse large B-cell lymphoma (DLBCL) patients: A real-world data analysis (ASH 2025) - "All patients received CAR–T–cell therapy with either tisagenlecleucel, lisocabtagene maraleucel, or axicabtagene ciloleucel. This real-world analysis demonstrates that DLBCL patients with pre-existing pulmonary and/or cardiac comorbidities have a significantly higher risk of developing CRS following CAR T-cell therapy compared to those without such comorbidities. Interestingly, despite the increased incidence of CRS, the presence of these comorbidities did not significantly impact short-term overall survival among patients who developed CRS. These findings underscore the importance of careful patient selection and vigilant monitoring for CRS in DLBCL patients with pulmonary and/or cardiac comorbidities undergoing CAR T-cell therapy."

Clinical • Cytokine release syndrome • Real-world • Real-world evidence • Asthma • Atherosclerosis • B Cell Lymphoma • Cardiovascular • Chronic Obstructive Pulmonary Disease • Diffuse Large B Cell Lymphoma • Heart Failure • Hematological Malignancies • Hypertension • Immunology • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Obstructive Sleep Apnea • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis • Sleep Apnea • Sleep Disorder • Systemic Inflammatory Response Syndrome

Real-world patterns of secondary malignancies and relapse following CAR T-cell therapy: A faers pharmacovigilance analysis (ASH 2025) - "Six CAR T-cell products have been approved by the U.S. Food and Drug Administration (FDA) to date: tisagenlecleucel (Tisa-cel), axicabtagene ciloleucel (Axi-cel), brexucabtagene autoleucel (Brexu-cel), lisocabtagene maraleucel (Liso-cel), ciltacabtagene autoleucel (Cilta-cel), and idecabtagene vicleucel (Ida-cel), for pediatric and adult B-cell acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma, follicular lymphoma and mantle cell lymphoma. Our FAERS analysis reveals distinct patterns of secondary primary malignancies and relapsed diseases following CAR T-cell therapy in real-world settings. The identification of myelodysplastic syndromes, cutaneous neoplasms, and rare T-cell or solid tumors highlights the need for vigilant post-therapy surveillance."

Adverse events • CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Basal Cell Carcinoma • Brain Cancer • Carcinoid Tumor • Diffuse Large B Cell Lymphoma • Endocrine Cancer • Eye Cancer • Follicular Lymphoma • Gastric Cancer • Glioblastoma • Glioneuronal Tumor • Head and Neck Cancer • Hematological Malignancies • Kaposi Sarcoma • Leiomyosarcoma • Leukemia • Lung Cancer • Lymphoma • Mantle Cell Lymphoma • Merkel Cell Carcinoma • Multiple Myeloma • Myelodysplastic Syndrome • Neuroendocrine Carcinoma • Non-Hodgkin’s Lymphoma • Non-melanoma Skin Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Peripheral T-cell Lymphoma • Rhabdomyosarcoma • Sarcoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer • T Cell Non-Hodgkin Lymphoma

Tocilizumab prophylaxis in patients receiving CAR-T cell immunotherapy for hematological malignancies: A systematic review and meta-analysis (ASH 2025) - "Four studies examining 91 patients with hematological malignancies (B-cell non-Hodgkin lymphomas: 76, ALL: 6, in 9 not specified) receiving tocilizumab prophylaxis (1 dose, 8 mg/kg) before CAR-T therapy (Axicabtagene ciloleucel: 38, Tisagenlecleucel: 2, other CD19-CAR-T cell products: 43, in 8 not specified) were included in the qualitative analysis. Based on these data, tocilizumab prophylaxis prior to infusion in patients who receive CAR-T cell immunotherapy can significantly decrease the risk of both any grade and grade >2 CRS. ICANS incidence was similar to ongoing published data and more than half of patients receiving tocilizumab prophylaxis achieved PFS. The need for larger, randomized controlled trials to confirm the observed effects and determine the impact of prophylactic tocilizumab on OS, TRM, adverse events, and infectious complications is warranted."

CAR T-Cell Therapy • Retrospective data • Review • Acute Lymphocytic Leukemia • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • IL6

Endocrine adverse events following CAR-T cell therapies: A pharmacovigilance analysis in the real-world setting utilizing the faers database (ASH 2025) - "CAR-T products analyzed included axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, ciltacabtagene autoleucel, idecabtagene vicleucel, and lisocabtagene maraleucel. This FAERS-based real-world analysis identifies relevant endocrine toxicities linked to CAR-T therapies, with strongest associations observed for axicabtagene ciloleucel and tisagenlecleucel. Immune-mediated dysfunction in the pituitary and thyroid axes appears most prominent. These findings support the need for increased endocrine monitoring post-CAR-T and suggest a class-wide effect with further prospective study."

Adverse events • CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Cushing’s Disease • Diabetes • Endocrine Disorders • Hematological Malignancies • Immunology • Metabolic Disorders • Nephrology • Renal Disease

Comparative analysis of CAR-T cell therapies across lymphoma subtypes: Efficacy, safety, and future perspectives (ASH 2025) - "Toxicity varied by costimulatory domain: CD28-based constructs (axi-cel) were associated with higher rates of CRS and immune effector cell-associated neurotoxicity syndrome than 4-1BB-based (costimulatorydomain) constructs (liso-cel, tisa-cel)...In mantle cell lymphoma (MCL), brexucabtagene autoleucel reduced or eliminated cancer in 93% of patients, with complete disappearance seen in 67%... C AR-T therapy offers subtype-specific advantages, with FL showing higher response rates and MCL demonstrating superior progression-free survival. While efficacy is well established, toxicity and relapse remain the key concerns. Costimulatory domains influence toxicity, and dual-target CAR-Ts may mitigate antigen escape."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • CD22

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study (ASH 2025) - "All HBV-positive patients received prophylactic antiviral treatment, predominantly with lamivudine (>90%)...Axi-cel was the most frequently used CAR-T product (53.5%), followed by tisa-cel (32.8%), brexu-cel (12.6%), and liso-cel (1.2%)...The lower incidence of CRS and milder ICANS severity observed in HBV-positive patients may point to potential immunomodulatory effects exerted by OBI status and/or antiviral prophylaxis. Systematic HBV screening and appropriate antiviral prophylaxis remain essential to minimize the rare risk of viral reactivation."

CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hepatitis B • Hepatology • High-grade B-cell lymphoma • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma

Absolute lymphocyte count (ALC) at apheresis and infusion as a predictor of safety and efficacy for multiple myeloma and B cell malignancies post CAR-T therapy (ASH 2025) - "72% of the population had diffuse large B-cell lymphoma (DLBCL) and 65% of the cohort received axicabtagene ciloleucel...68% of this group had IgG MM and 52% of the cohort received idecabtagene vicleucel...56% of the ALL cohort received brexucabtagene autoleucel... ALC at time of apheresis and infusion may influence progression/survival status and incidence of CRS/ICANS. ALC at apheresis may be predictive of the quantity of lymphocytes being collected and ALC at infusion may effect CAR-T expansion by impacting the cellular immune environment. These findings were more pronounced in the NHL cohort than in the MM or ALL cohorts, which may reflect the effect of disease specific characteristics as well as the confounder of circulating leukemic cells registering as lymphocytes."

Clinical • Acute Lymphocytic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Which inflammation matters? distinct risk signatures before CAR-T cell therapy and the role of inflamix (ASH 2025) - "Next, we evaluated potential differences in the use of tocilizumab, steroid therapy, and intensive care unit (ICU) hospitalization between the two groups...Overall, 65 patients (71%) received axicabtagene ciloleucel (axicel), and 27 patients (29%) received tisagenlecleucel (tisacel)...Its divergence from mEASIX and CAR-HEMATOTOX suggests that it reflects a distinct inflammatory profile. This underscores the importance of incorporating multiple biomarkers to enhance risk stratification."

CAR T-Cell Therapy • IO biomarker • Hematological Disorders • Hematological Malignancies • Inflammation • Lymphoma • Neutropenia

Real-world outcomes of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) following CAR T-cell therapy: A multicenter retrospective study from the trinetx global network (ASH 2025) - "The analysis included data from 172 million patients across 151 healthcare organizations worldwide, predominantly academic centers in the U.S. Eligible patients had a confirmed diagnosis of R/R DLBCL, received ≥2 prior lines of systemic therapy including CAR T-cell therapy (axicabtagene ciloleucel or lisocabtagene maraleucel), were treated with epcoritamab, had an ECOG performance status of 0–2, and had ≥30 days of follow-up...Grade 3–4 CRS and ICANS occurred in ~4.1% of patients, and 25% received tocilizumab... In this real-world cohort, epcoritamab demonstrated favorable short-term survival in patients with R/R DLBCL following CAR T-cell therapy, mirroring results from the EPCORE NHL-1 trial. By limiting the cohort to patients with ECOG 0–2 and excluding prior transplant recipients, the study population closely resembled clinical trial eligibility. These findings support the broader applicability of epcoritamab in routine practice and highlight the importance of early..."

CAR T-Cell Therapy • Real-world • Real-world evidence • Retrospective data • Atrial Fibrillation • B Cell Lymphoma • Cardiovascular • Congestive Heart Failure • Diffuse Large B Cell Lymphoma • Heart Failure • Infectious Disease • Influenza • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Pneumonia • Respiratory Diseases • Thrombocytopenia

Real world chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma: The Australian experience (ASH 2025) - "Pts received commercial CD19-directed CAR-T cell therapy; Axicabtagene ciloleucel (Axi-cel) or Tisagenlecleucel (Tisa-cel)...Bridging therapy was administered in 70% of pts, comprising checkpoint inhibitor 10%, immunochemotherapy 20%, corticosteroids-only 10%, polatuzumab 10% and radiotherapy 20%... Eleven pts underwent leukapheresis and were eligible for analysis; with 10 pts proceeding to CAR-T infusion. The median age of the cohort was 67 years with a male predominance (89%). 50% had primary refractory disease with 80% refractory to ≥2 prior therapies."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • T Cell Histiocyte Rich Large B Cell Lymphoma